Bioceres Crop Solutions Reports Fiscal Second Quarter 2025 Financial and Operational Results

ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal second quarter ended December 31, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Revenues in 2Q25 totaled $106.7 million, down from quarterly record-high of $140.2 million in 2Q24, as tight farm economics and elevated channel inventories in Argentina — a decisive market for the quarter — significantly contracted the overall market for crop protection and specialty fertilizers. This led to a year-over-year reduction in sales of non-core CP products and micro-beaded fertilizers, roughly in line with the market decline. Operating profit was $7.9 million and net income was $0.6 million. Adjusted EBITDA for the quarter was $15.4 million, mainly driven by top-line and gross profit performance from Argentina. New strategy defined for seed business, exiting breeding and seed production activities to focus on trait development and key partnerships for market access: Alliance with GDM to use Verdeca’s patented platform to develop and market next generation varieties that combine superior agronomic performance with biotech traits. Trigall Genetics to focus on HB4 trait development in wheat and transfer breeding programs to Florimond Desprez. Rights to HB4 technology outside of Latin America are now fully controlled by Bioceres. Milen Marinov appointed Chief Commercial Officer (CCO). Management Review Mr. Federico Trucco, Bioceres´ Chief Executive Officer, commented: “Calendar year 2024 has been a reminder that growth, at least in the agriculture industry, is seldom linear. The conditions in Argentina, which remains our primary market, have proven increasingly difficult. This has affected the performance of our fiscal first half, a period during which we are more exposed to sales in the Southern Hemisphere. While we have maintained or gained market share in all our key product segments, we believe this macro environment provides unique opportunities to unlock the full commercial potential of our differentiated portfolio of products and technologies. As a result, we are implementing two significant strategic changes. First, we are appointing Milen Marinov, who previously served as our EVP of Commercial for North America, as our new Chief Commercial Officer. Milen’s past experience in key commercial development roles in Valagro and then Syngenta, as well as his track record with us since joining the Profarm team last year, positions him uniquely to help us streamline our commercial operations, accelerate the on-boarding of new commercial partners, and better prioritize, diversify and synchronize our portfolio opportunities for profitable growth. Second, in the seed segment, we are sharpening our focus on what we do best: sourcing cutting-edge science and cost-effectively developing patented seed traits until commercial approval. We have made the strategic decision to exit breeding, seed production and seed sales and will instead partner with industry leaders who are better structured for these activities. As a first step in this new strategy, we are announcing a strategic agreement with GDM for the development of new soybean solutions, with exclusive rights outside the drought tolerance space. Additionally, we are a redefining the scope of our wheat joint venture with Florimond Desprez, exiting conventional breeding operations in Argentina and Australia, while directly licensing our HB4 wheat technology to partners outside of Latin America. We believe these initiatives will enable us to scale our current and future seed technologies more rapidly and efficiently.” Mr. Enrique Lopez Lecube, Bioceres´ Chief Financial Officer, noted: “While our fiscal first half results reflect the challenges posed by the Argentine market, particularly the decline in farmer economics driven by lower commodity prices and weak yield forecasts, we view this setback as temporary. Argentine farmers faced significant pressure on their per-hectare income from summer crops due to these external factors, which was partially passed on to costs in the form of reduced use of fertilizers and crop protection products. This, in the context of a well-supplied ag-inputs market from aggressive purchasing in the prior season, resulted into price pressure and reduced spending on high-value technologies like ours. However, we are encouraged that we maintained our market share in key product families, despite the overall Argentine market contraction. We remain optimistic about our long-term prospects, driven by our commitment to developing and commercially scaling up innovative technologies that create value for end-users. We are also cognizant that successfully navigating this period of market volatility requires a strong focus on capital allocation, driving cost efficiencies to safeguard profitability, and transitioning towards a more asset-light business model. The strategic repositioning of our seed business and tighter inventory management are initial steps in this direction. In the near future we will continue to explore additional opportunities to enhance profitability and cash flows, ensuring we’re well-positioned to capitalize on the groundwork already made to support our global expansion as well as to benefit from the recovery of the Argentine market.” Key Financial Metrics Table 1: 2Q25 & 1H25 Key Financial Metrics (In millions of U.S. dollars) 2Q24 2Q25 %CHANGE 1H24 1H25 %CHANGE Revenue by Segment Crop Protection 71.2 55.2 (23%) 127.2 101.1 (20%) Seed and Integrated Products 32.2 23.3 (28%) 54.5 43.9 (20%) Crop Nutrition 36.8 28.2 (23%) 75.1 55.0 (27%) Total Revenue 140.2 106.7 (24%) 256.8 200.0 (22%) Gross Profit 51.5 45.1 (12%) 96.5 82.6 (14%) Gross Margin 37% 42% 557 bps 38% 41% 375 bps 2Q24 2Q25 %CHANGE 1H24 1H25 %CHANGE GAAP net income or loss 1.2 0.6 (51%) (1.4) (5.6) (287%) Adjusted EBITDA 24.1 15.4 (36%) 40.4 23.8 (41%) 2Q25 Summary: Total revenues in 2Q25 were $106.7 million, a 24% decline from the record $140.2 million in the same period last year. The downturn was primarily driven by performance in Argentina where tighter on-farm margins altered farmer purchasing behavior, leading to a significant contraction of the crop protection and specialty fertilizers markets compared to the prior year. Reduced end-user demand added to high channel inventories derived from aggressive purchases in the prior summer crop season, ahead of expectations of changes in macro conditions in Argentina. Non-core crop protection products and micro-beaded fertilizers were the main product categories affected by the market contraction in Argentina and explain the decline in Crop Protection and Crop Nutrition sales, albeit with a roughly stable market share for both categories. Sales in Seed and Integrated Products decreased on the back of reduced downstream grain sales in line with the strategic pivoting of the seed business, partially offset by seed treatment packs sales which showed a modest top-line growth in Argentina despite the market contraction dynamics. Revenues for the first half of FY25 declined by 22% compared to the year-ago period, primarily driven by the crop protection and specialty fertilizers market downturn in Argentina, although the decline was not at the expense of losing market share. Outside of Argentina, revenues showed a modest year-over-year increase in 2Q25 after an overperformance in 1Q25, leading to net growth in 1H25. Gross profit for the quarter was $45.1 million, a 12% decline year-over-year. The decline in revenues was buffered by an improved product mix, particularly in the Crop Nutrition and Seed and Integrated Products segments, as the company successfully maintained sales of higher-margin inoculants, biostimulants and seed treatment packs, as opposed to reduced sales of lower-margin micro-beaded fertilizers, non-core crop protection products and downstream grain sales. As a result, gross margin increased from 37% to 42%, compared to the previous year. Similarly, first-half gross margin increased from 38% to 41%, as core product families increased contribution to the product mix. Operating profit for the quarter was $7.9 million, with a net income of 0.6 million. Adjusted EBITDA1 for the quarter was $15.4 million, primarily driven by revenues and gross profit performance. For a full version of Bioceres’ second quarter fiscal year 2025 earnings release, click here. Second Quarter 2025 Earnings Conference Call Management will host a conference call and question-and-answer session, which will be accompanied by a presentation available during the webcast or accessed via the investor relations section of the company’s website. To access the call, please use the following information: Date: Wednesday, February 12, 2025 Please dial in 5-10 minutes prior to the start time to register and join. The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website here. A replay of the call will be available through February 19, 2025, following the conference. Toll Free Replay Number: 1-866-813-9403 International Replay Number: +44 204 525 0658 Replay ID: 783074 Time: 8:30 a.m. EST, 5:30 a.m. PST US Toll Free dial-in number: 1-833-470-1428 International dial-in numbers: Click here Conference ID: 525329 Webcast: Click here About Bioceres Crop Solutions Corp. Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation Crop Nutrition and Protection solutions. Through its HB4® program, the company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit here. Forward-Looking Statements This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial data, and any such forward-looking statements involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful and (ii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the company’s ability to achieve its strategic goals, including the uncertainties relating to the other factors that are described in the sections entitled “Risk Factors” in the company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law. Unaudited Consolidated Statement of Comprehensive Income (Figures in million of U.S. dollars) Three-month period ended 12/31/2024 Three-month period ended 12/31/2023 Revenues from contracts with customers 106.8 140.3 Initial recognition and changes in the fair value of biological assets at the point of harvest (0.1) (0.1) Cost of sales (61.6) (88.7) Gross profit 45.1 51.5 % Gross profit 42% 37% Operating expenses (37.4) (34.8) Share of profit of JV 0.4 2.1 Change in net realizable value of agricultural products (0.8) (0.7) Other income or expenses, net 0.5 (1.2) Operating profit 7.9 16.8 Financial result (7.5) (7.3) Profit/(loss) before income tax 0.4 9.6 Income tax 0.2 (8.3) Profit/(loss) for the period 0.6 1.2 Other comprehensive loss (0.2) 0.5 Total comprehensive profit/(loss) 0.4 1.7 Profit/(loss) for the period attributable to: Equity holders of the parent 0.1 0.1 Non-controlling interests 0.5 1.1 0.6 1.2 Total comprehensive profit/(loss) attributable to: Equity holders of the parent 0.2 0.5 Non-controlling interests 0.2 1.2 0.4 1.7 Weighted average number of shares Basic 62.8 62.8 Diluted 63.2 63.9 Unaudited Consolidated Statement of Financial Position (Figures in million of U.S. dollars) ASSETS 12/31/2024 06/30/2024 CURRENT ASSETS Cash and cash equivalents 29.2 44.5 Other financial assets 2.0 11.7 Trade receivables 227.7 207.3 Other receivables 17.2 18.3 Recoverable income taxes 1.5 0.7 Inventories 101.8 125.9 Biological assets 4.4 0.3 Total current assets 383.7 408.7 NON-CURRENT ASSETS Other financial assets 0.8 0.6 Other receivables 18.2 18.0 Recoverable income taxes 0.0 0.0 Deferred tax assets 12.1 9.7 Investments in joint ventures and associates 40.0 39.8 Investment properties 0.6 0.6 Property, plant and equipment 74.9 74.6 Intangible assets 176.3 176.9 Goodwill 112.2 112.2 Right of use asset 16.3 11.6 Total non-current assets 451.4 443.9 Total assets 835.2 852.5 LIABILITIES CURRENT LIABILITIES Trade and other payables 144.0 168.7 Borrowings 119.2 136.7 Employee benefits and social security 8.2 7.3 Deferred revenue and advances from customers 2.9 3.9 Income tax payable 5.9 4.8 Consideration for acquisition 3.2 4.6 Lease liabilities 5.3 3.1 Total current liabilities 288.8 329.3 NON-CURRENT LIABILITIES Borrowings 66.9 42.1 Deferred revenue and advances from customers 1.9 1.9 Joint ventures and associates 0.7 0.3 Deferred tax liabilities 33.2 35.0 Provisions 1.1 1.3 Consideration for acquisition 2.2 2.3 Secured notes 83.4 80.8 Lease liabilities 10.8 8.2 Total non-current liabilities 200.4 171.9 Total liabilities 489.2 501.2 EQUITY Equity attributable to owners of the parent 309.4 315.0 Non-controlling interests 36.6 36.3 Total equity 346.0 351.4 Total equity and liabilities 835.2 852.5

Bioceres Crop Solutions Reports Fiscal Second Quarter 2025 Financial and Operational Results

FAQ

Why Neutral?

How important is it?

Why Short Term?

Related Companies

Related News